Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATINA: Palbociclib + Anti-HER2 + Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer
NCT02947685Phase 3Active, not recruiting
- Sponsor
- Alliance Foundation Trials
- Start
- Jun 2017
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by Alliance Foundation Trials. Primary endpoint: Progression-free Survival. Started Jun 2017; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02947685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947685.